Pay in 4 interest-free payments of $5.77 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Dosage: 1-2 mg/day subcutaneous injection
GHK-Cu additionally downregulates scar formation and fibrotic processes, suppresses harmful cytokines and signal transduction pathways (such as TGF-?1/Smad), and supports angiogenesis and stem cell differentiation
It boosts the nitric oxide (NO) system and raises growth factors like VEGF and FGF to help new blood vessels form at injury sites
This work was supported by R35HL139726 (ESN), R01HL156670 (CCS), K24HL150630 (CCS), and 5R01HL157973 (SF)
In a preclinical melanoma model, CB-839 significantly improved the therapeutic efficacy of adoptive T-cell therapy and immune checkpoint inhibitors (anti-PD1 and anti-CTLA4), triggering a superior immune response (Varghese et al., 2021)
Timmermans notes that the patent for BPC-157 expired long ago, which means that no company presently has a clear profit motive to spend millions to fund human studies
US$ 27.04
US$ 27.53
US$ 28.39
US$ 29.75
US$ 20.80
